新冠后肺纤维化。这是真实存在的威胁吗？
Post covid 19 pulmonary fibrosis. Is it real threat?
机构信息
Department of Pulmonary Medicine, AIIMS Patna, 801505, India.
Department of Pulmonary Medicine, AIIMS Patna, 801505, India.
出版信息
Indian J Tuberc. 2021 Jul;68(3):330-333. doi: 10.1016/j.ijtb.2020.11.003. Epub 2020 Nov 10.
Abstract
After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.
摘要
在 COVID-19 爆发后，全球越来越多的 COVID-19 幸存者在临床检测呈阴性后仍继续与疾病的症状作斗争。在我们与这场大流行作斗争的过程中，具有挑战性的部分是管理 COVID-19 后遗症，这些后遗症可能从疲劳和身体疼痛到肺纤维化不等。这篇综述介绍了新冠后肺纤维化的潜在机制、危险因素、疾病过程和治疗选择。需要 ICU 护理和机械通气的老年患者发生肺纤维化的风险最高。目前，尚无经充分证实的方法可用于治疗 COVID-19 后炎症性肺纤维化。
相似文献
1
Post covid 19 pulmonary fibrosis. Is it real threat?
Indian J Tuberc. 2021 Jul;68(3):330-333. doi: 10.1016/j.ijtb.2020.11.003. Epub 2020 Nov 10.
2
The Management of Pulmonary Fibrosis in COVID-19.
Acta Med Indones. 2021 Apr;53(2):233-241.
3
Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study.
Medicine (Baltimore). 2022 Jan 21;101(3):e28639. doi: 10.1097/MD.0000000000028639.
4
Pulmonary fibrosis secondary to COVID-19: a narrative review.
Expert Rev Respir Med. 2021 Jun;15(6):791-803. doi: 10.1080/17476348.2021.1916472. Epub 2021 Apr 27.
5
Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.
Infect Dis Poverty. 2021 Mar 18;10(1):31. doi: 10.1186/s40249-021-00813-8.
6
Pulmonary fibrosis followed by severe pneumonia in patients with COVID-19 infection requiring mechanical ventilation: a prospective multicentre study.
BMJ Open Respir Res. 2024 Oct 4;11(1):e002538. doi: 10.1136/bmjresp-2024-002538.
7
[Pulmonary fibrosis in patients with COVID-19: A review].
Ter Arkh. 2022 Dec 26;94(11):1333-1339. doi: 10.26442/00403660.2022.11.201943.
8
Pulmonary Fibrosis Caused by Severe COVID-19 Infection: Discharge May Not Be The End of Treatment.
Acta Med Indones. 2021 Apr;53(2):141-142.
9
Progressive Pulmonary Fibrosis After Non-Critical COVID-19: A Case Report.
Am J Case Rep. 2021 Dec 1;22:e933458. doi: 10.12659/AJCR.933458.
10
Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis.
Respir Med. 2021 Nov;188:106602. doi: 10.1016/j.rmed.2021.106602. Epub 2021 Sep 8.
引用本文的文献
1
A collaborative study on rehabilitating altered pulmonary functions of COVID-19 survivors with selective yoga regime.
J Family Med Prim Care. 2025 May;14(5):1722-1727. doi: 10.4103/jfmpc.jfmpc_1221_24. Epub 2025 May 31.
2
Presence and Evolution of Radiological Changes at 6 and 12 Months After COVID-19 Pneumonia and Their Risk Factors.
Medicina (Kaunas). 2025 Feb 22;61(3):382. doi: 10.3390/medicina61030382.
3
Integration of pharmacodynamics, network pharmacology and metabolomics to elucidate the effect and mechanism of Jingfang Granule in the treatment of Paraquat induced Pulmonary fibrosis.
PLoS One. 2025 Feb 18;20(2):e0318246. doi: 10.1371/journal.pone.0318246. eCollection 2025.
4
Impact of underlying diseases and complications on COVID-19 mortality in South Korea: analysis of national health insurance service data.
Arch Public Health. 2025 Jan 23;83(1):20. doi: 10.1186/s13690-025-01509-3.
5
Predictors of the presence of radiological abnormalities 6 months after severe COVID-19 pneumonia.
BMC Infect Dis. 2024 Aug 29;24(1):883. doi: 10.1186/s12879-024-09767-2.
6
Association between dietary niacin intake and lung function among American adults: A cross-sectional analysis from national health and nutrition examination survey, 2007-2012.
Heliyon. 2024 Jun 22;10(13):e33482. doi: 10.1016/j.heliyon.2024.e33482. eCollection 2024 Jul 15.
7
Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.
Int J Environ Res Public Health. 2024 May 19;21(5):647. doi: 10.3390/ijerph21050647.
8
Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.
AAPS PharmSciTech. 2024 Apr 8;25(4):78. doi: 10.1208/s12249-024-02793-y.
9
Quantification of fibrosis extend and airspace availability in lung: A semi-automatic ImageJ/Fiji toolbox.
PLoS One. 2024 Feb 29;19(2):e0298015. doi: 10.1371/journal.pone.0298015. eCollection 2024.
10
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.
Int J Mol Sci. 2024 Jan 26;25(3):1562. doi: 10.3390/ijms25031562.
本文引用的文献
1
Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery.
EClinicalMedicine. 2020 Aug;25:100463. doi: 10.1016/j.eclinm.2020.100463. Epub 2020 Jul 15.
2
Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge.
Eur Respir J. 2020 Jul 23;56(1). doi: 10.1183/13993003.01832-2020. Print 2020 Jul.
3
Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City, Zhejiang, China.
Ann Am Thorac Soc. 2020 Oct;17(10):1231-1237. doi: 10.1513/AnnalsATS.202004-324OC.
4
Persistent Symptoms in Patients After Acute COVID-19.
JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
5
Impaired pulmonary function in discharged patients with COVID-19: more work ahead.
Eur Respir J. 2020 Jul 23;56(1). doi: 10.1183/13993003.02194-2020. Print 2020 Jul.
6
COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead.
Eur J Prev Cardiol. 2020 Sep;27(13):1442-1446. doi: 10.1177/2047487320932695. Epub 2020 Jun 17.
7
Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(1):85-90. doi: 10.36141/svdld.v35i1.6393. Epub 2018 Apr 28.
8
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
Lancet Respir Med. 2020 Aug;8(8):807-815. doi: 10.1016/S2213-2600(20)30225-3. Epub 2020 May 15.
9
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.01217-2020. Print 2020 Jun.
10
Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.
Hepatology. 2020 Sep;72(3):1102-1108. doi: 10.1002/hep.31307.
Zotero 插件